Home > Boards > US Listed > Biotechs >

Tonix Pharmaceuticals Holding Corp (TNXP)

TNXP RSS Feed
Add TNXP Price Alert      Hide Sticky   Hide Intro
Moderator: mick, powerbattles, Iron heart, UOENO
Search This Board: 
Last Post: 9/18/2020 11:29:25 PM - Followers: 239 - Board type: Free - Posts Today: 0



06-20-2020 T-CELL THEORY INSIDE T-CELL KILLS VIRUS FROM WITHIN !!!!!
$TNXP DIRECTORS, ONTRACK FOR T-CELLS. I WAS WATCHING FOX T.V. AND T-CELLS

ATTACK VIRUS FROM WITHIN NOT OUTSIDE OF CELLS.

Plan to Produce Blueprint of How the Human Immune System Responds to Infection Caused by SAR-CoV-2, the Virus that Causes COVID-19

Results Expected to Support Tonix’s Anticipated Regulatory Filings for
TNX-1800, a Live Replicating Virus Vaccine Designed to Elicit T Cell Immunity in Addition to Antibodies

THIS COULD BE HUGE HERE FOR THIS PLATFORM !!!!!

https://finance.yahoo.com/news/tonix-pharmaceuticals-southern-research-announce-110010137.html
$NK DOES THIS ONLY ONE DOING VIRUS FROM INSIDE T-CELL PER  Interview with Dr. Patrick Soon-Shiong 

06-20-2020

NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company),
a clinical-stage biopharmaceutical company, announced today an expansion of its strategic collaboration with Southern Research to include a study of

T cell immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19. 
The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix’s TNX-1800,
which is a live replicating virus vaccine designed to protect against COVID-19.  The data will support the interpretation of animal trial results with TNX-1800,
which are expected in the fourth quarter of 2020 and subsequent human trials.

“More than 200 years of vaccine experience, beginning with Dr. Edward Jenner’s landmark discoveries with horsepox and cowpox vaccines, have shown that
T cell eliciting vaccines are particularly effective against viruses,” said Seth Lederman, M.D., President and CEO of Tonix. 
“We believe that protective vaccines against the SARS-CoV-2 virus will be similar in that regard. 
The data we plan to collect from recovered and asymptomatic COVID-19 volunteers will inform vaccine development on how to safely
provide to vaccine recipients the same immune responses that others got from recovering from actual CoV-2 infection. 
If approved by the U.S. Food and Drug Administration (FDA) for use in healthy, non-pregnant adults without moderate or severe eczema,

TNX-1800 would feature single-dose immunity without the use of adjuvants, ease of manufacturing on readily available systems,
and glass-sparing distribution since we believe 100 doses of TNX-1800 could be packaged in a single vial.
Our goal with TNX-1800 is to develop a vaccine that is well tolerated, produces strong, long-lasting immunity, and can be rapidly and broadly deployed.”

ON FOX T.V.MARIA INTERVIEW  CEO OF $ NK---Soon-Shiong is also the CEO of the Nantworks 
NantKwest (NK)
Dr. Patrick-Soon-Shiong Wikipedia Bio

Forbes Profile   Patrick Soon-Shiong

Excellent Interview    Larry King Live 
 

They have the technology     NantKwest   T-CELL THEORY FROM WITHIN THE T-CELL

Tonix Pharmaceuticals Holding Corp :
06-20-2020
$TNXP DIRECTORS, ONTRACK FOR T-CELLS. I WAS WATCHING FOX T.V. AND T-CELLS

ATTACK VIRUS FROM WITHIN NOT OUTSIDE OF CELLS.

 
$TNXP; Financials=As of May 11, 2020, the Company has an aggregate of 52,302,475 shares of common stock outstanding.

$TNXP
As of March 31, 2020, the Company had cash and cash equivalents of $30.7 million, compared to $11.2 million at December 31, 2019. 
The Company had no debt outstanding at March 31, 2020.
Debt/Eq 0.00-LT Debt/Eq 0.00, Employees 16
Book/sh 1.52, 52W Range 0.39 - 24.90, SELLING 1/2 X'S BOOK.
[BUYER] Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4

LEDERMAN SETH Chief Executive Officer Dec 03 Buy 1.16 20,000 23,180 23,267 Dec 04 07:00 AM

https://finviz.com/quote.ashx?t=TNXP
 

Attractive Product with $650 Million Potential !

Tonix Pharmaceuticals Holding Corp (TNXP)

HUGE NEWS!
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)

TNXP Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL 

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX...

 
Stockholders' equity:    
Preferred stock:
5,000,000 shares authorized Series A Convertible Preferred stock, 11,984 shares designated; 0 and 9,856 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively

 
   
Common stock:
150,000,000 shares authorized;
6,338,320 and 3,251,970 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively, and 23,792 and 1,758 shares to be issued as of June 30, 2019 and December 31, 2018, respectively
 

Source: https://ir.tonixpharma.com/all-sec-filings/content/0001387131-19-005974/0001387131-19-005974.pdf


On October 31, 2019, the Company filed a Certificate of Change with the Nevada Secretary of State, which was effective November 1, 2019. Pursuant to the Certificate of Change, the Company effected a 1-for-10 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 15,717,402 outstanding shares of the Company’s common stock were exchanged for 1,575,246 shares of the Company’s common stock. In connection with the reverse stock split, the Company issued an additional 3,457 shares of the Company’s common stock due to rounding. Furthermore, pursuant to the Certificate of Change, the number of authorized shares of common stock was reduced from 150 million to 15 million. All per share amounts and number of shares in the condensed consolidated financial statements and related notes have been retroactively restated to reflect the reverse stock split.

Source: https://ir.tonixpharma.com/all-sec-filings/content/0001387131-19-008474/0001387131-19-008474.pdf


 
   
 

Financials

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
June 30, 2019 Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 12,150 $ 25,034
 

Website
https://www.tonixpharma.com

 

Investor Presentations
https://ir.tonixpharma.com/investor-presentations

Overview

Summary

Phase 3 development of new bedtime treatment for PTSD, including militaryrelated PTSD
• Major unmet need; ~12 million Americans annually
• Benefited from FDA 505(b)(2) NDA approval requirement

Complimentary day-time PTSD treatment in development
• Leverages development expertise in PTSD, i.e., regulatory, trial recruitment and execution

Fibromyalgia bedtime treatment in development
• New Phase 3 study design features discussed with FDA (April 2019 FDA Meeting Minutes)
• TNX-102 SL 5.6 mg (twice the dose previously studied in FM Phase 2/3 trials) will be studied in Phase 3 to support the indication

New indication in development for agitation in Alzheimer’s Disease
• Unmet medical need, no approved drug available
• Fast Track Phase 2/3 ready program

Innovative vaccine in development to prevent Smallpox
• Opportunity to supply stockpiling requirement; short development path
• Studies in mice suggest improved safety profile



Conclusion and Valuation

The U.S. military’s intense interest in identifying safe and effective PTSD treatments is important for Tonix, as the AtEase study is the only controlled clinical trial to show a benefit in treating military related PTSD. If those results can be duplicated in the HONOR study (and Tonmya® gets approved), the Department of Defense and the VA would likely be very interested in getting the treatment to military personnel and veterans who suffer from PTSD.

Our valuation for Tonix is derived from a probability adjusted discounted cash flow model that takes into account potential future revenues from the sale of TNX-102 SL in PTSD. Of the approximately 8.6 million individuals in the U.S. who suffer from PTSD, it’s estimated that approximately 20% seek treatment. With a peak market share of only 6%, we currently estimate that peak sales of $650 million are possible. Using a discount rate of 18% and a 50% probability of approval leads to a net present value for the PTSD program of $67 million. Combined with the company’s current cash position and dividing by a reasonable fully diluted share count of 8.1 million shares leads to a valuation of approximately $13 per share.


Insider & Institutional Ownership :

Rosalind Advisors, Inc. 553 908
Baker Bros. Advisors LP 510 922
B. Riley Capital Management LLC 378 138
Opaleye Management, Inc. 370 000
Empery Asset Management LP 315 000
The Vanguard Group, Inc. 184 377
Heights Capital Management, Inc. 89 713
Seth Lederman, MD 83 400
Ernest Mario, PhD 69 718
Kingdon Capital Management LLC 64 549

-----------------------

IR Contact Information

Investor Relations
TONIX Pharmaceuticals
investor.relations@tonixpharma.com

Transfer Agent
vStock Transfer
77 Spruce Street
Suite 201
Cedarhurst, NY 11516
T: 212-828-8436
www.vstocktransfer.com

---------------------------

If you guys want that the stock moving even faster then put your shares on high GTC sell order like $10
this helps to prevent your shares from being shorted and more important your shares wouldnt be available
on the market so if all shareholders doing that then it would help this stock to make bigger jumps in share price on good news.
This works good especially on stocks like TNXP which has only 10 million shares outstanding.
Thank you

How to Prevent your Shares Holdings from being Shorted

http://www.contracts-for-difference.com/Borrowing-lending-shares.html

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
PARTNER
LINKS, https://southernresearch.org/drug-development/

https://southernresearch.org/drug-discovery/

https://southernresearch.org/engineering/

https://southernresearch.org/eande/

https://southernresearch.org/medtech/

https://southernresearch.org/stem/

https://southernresearch.org/events/

https://southernresearch.org/newsletter/

https://southernresearch.org/magazine/

https://southernresearch.org/news/category/cancer-research/
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

2,$TNXP,from website. Southern Research, Tonix team to develop potential vaccine against new coronavirus
FEBRUARY 26, 2020 | BY JERRY UNDERWOOD | DRUG DEVELOPMENT
Southern Research announced today that it has entered into a strategic collaboration with New York-based Tonix Pharmaceuticals Holding Corp.,
a clinical-stage biopharmaceutical company, to support the development of a vaccine, […]

https://southernresearch.org/drug-development/





TNXP Daily Chart



TONIX PHARMACEUTICALS HOLDING CORP. 8-K

https://www.sec.gov/Archives/edgar/data/1430306/000138713120003042/ex99-1.htm









https://finviz.com/quote.ashx?t=tnxp&ty=c&ta=1&p=d




 

DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.


 






 

 
TNXP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TNXP News: Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19? 09/17/2020 09:17:24 AM
TNXP News: Current Report Filing (8-k) 09/16/2020 04:08:28 PM
TNXP News: Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to S... 09/15/2020 09:00:10 AM
TNXP News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/04/2020 09:02:48 AM
TNXP News: Current Report Filing (8-k) 09/04/2020 09:01:52 AM
PostSubject
#7087  Sticky Note $TNXP #2 Tonix Pharmaceuticals to Host Live Webinar: mick 09/17/20 11:44:53 AM
#4651  Sticky Note Tonix Pharmaceuticals reveals exciting upcoming milestones in its powerbattles 03/10/20 02:41:49 PM
#3341  Sticky Note Tonix Pharmaceuticals Announces Research Collaboration with Southern Research [SMART MONEY] 02/26/20 07:16:18 AM
#7096   Clay you always come in and short stocks csiderydah 09/18/20 05:55:12 PM
#7095   BREAKING NEWS: $TNXP What Are The Best Penny whytestocks 09/17/20 07:45:20 PM
#7094   Breaking News: $TNXP Tonix Pharmaceuticals to Host Live whytestocks 09/17/20 07:30:14 PM
#7093   * * $TNXP Video Chart 09-17-2020 * * ClayTrader 09/17/20 05:25:49 PM
#7092   stair steppin week Aarons 09/17/20 12:40:34 PM
#7091   $TNXP EXCERPT [ALSO COWPOX] TNX-801*, live horsepox virus mick 09/17/20 12:00:33 PM
#7090   $TNXP I DID DIBBS AGAIN !!!!! mick 09/17/20 11:54:05 AM
#7089   $TNXP Tonix Pharmaceuticals Reports Second Quarter 2020 Financial mick 09/17/20 11:48:45 AM
#7088   $TNXP IN DIS NEWS MILESTONE FOR THEM IMHO. mick 09/17/20 11:46:47 AM
#7087   $TNXP #2 Tonix Pharmaceuticals to Host Live Webinar: mick 09/17/20 11:44:53 AM
#7086   AH MAYBE ????? $TNXP Tonix Pharmaceuticals to Host mick 09/17/20 11:32:07 AM
#7085   Hit 1.08 on double average daily volume 12 XWAVXALMIMAN 09/17/20 10:10:04 AM
#7084   $TNXP IT IS AH STARTER MY FRIEND mick 09/17/20 08:32:34 AM
#7083   $TNXP News: Current Report Filing (8-k) 09/16/2020 04:08:28 PM mick 09/17/20 08:14:24 AM
#7082   $TNXP 8-K YESTERDAY mick 09/17/20 08:12:59 AM
#7081   News on the morning wires??? hmmmmm kingsransome 09/17/20 06:11:17 AM
#7080   Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an AllGold818 09/16/20 07:20:07 PM
#7079   $TNXP GOOD NEWS ITEM MY FRIEND[Enrollment underway in mick 09/15/20 08:09:24 PM
#7078   Enrollment underway in Tonix Pharma's observational study in COVID-19 AllGold818 09/15/20 07:30:35 PM
#7077   Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an UOENO 09/15/20 09:09:27 AM
#7076   I belive they are good for 1 year. daleb2130 09/14/20 08:55:56 PM
#7075   That was great news but how long do XWAVXALMIMAN 09/14/20 07:58:35 PM
#7074   And there is this. Nasdaq compliant daleb2130 09/14/20 02:02:23 PM
#7073   They have no reason to do a RS. daleb2130 09/14/20 02:00:57 PM
#7072   I’m OK with reverse split. It didn’t hurt XWAVXALMIMAN 09/14/20 10:05:42 AM
#7071   Loser huh? You will be the loser Nomoneyhere 09/13/20 01:27:58 AM
#7070   Loser. You have no money to buy my XWAVXALMIMAN 09/12/20 12:33:39 AM
#7064   Sell people! Nomoneyhere 09/11/20 02:31:20 PM
#7063   And there you go...down another 3%! Who Nomoneyhere 09/11/20 09:42:27 AM
#7062   Down 3% daily on avg. How long Nomoneyhere 09/11/20 06:50:04 AM
#7061   $TNXP smart !!!!! mick 09/10/20 10:56:48 AM
#7060   all will be surprised one day. i did mick 09/10/20 10:56:15 AM
#7059   $TNXP has animal cure 'horsepox' 'cowpox' should checkout. mick 09/10/20 10:54:35 AM
#7058   $TNXP covid-19 big time selloff but virus is mick 09/10/20 10:51:41 AM
#7057   i just give outstanding data. $TNXP “More than mick 09/10/20 10:50:08 AM
#7056   Adding on dips daleb2130 09/09/20 03:15:38 PM
#7055   There may have been a pump and dump, UOENO 09/09/20 02:55:38 PM
#7054   Mick “the moderator” is the only person who Nomoneyhere 09/09/20 02:15:54 PM
#7053   What a pile of **** this is. Nomoneyhere 09/09/20 01:33:39 PM
#7052   $TNXP DA VIRUS COVID-19 mick 09/07/20 10:05:07 PM
#7051   Coronavirus Vaccine Tonix Pharmaceuticals Holding Corp (TNXP) AllGold818 09/07/20 07:59:16 PM
#7050   $0.01 *w* BREAKOUT www.stockscores.com/chart.asp?TickerSymbol=TNXP&TimeRa mick 09/06/20 01:45:57 PM
#7049   Tonix Pharmaceutical (TNXP) mick 09/05/20 04:25:14 PM
#7048   $TNXP i missed dis. mick 09/04/20 03:45:30 PM
#7047   JUST IN: $TNXP Tonix Pharmaceuticals Initiates Enrollment in whytestocks 09/03/20 10:15:12 PM
#7046   Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal AllGold818 09/03/20 08:46:10 PM
#7045   nice pipeline platform horsepox TNXP mick 08/31/20 11:37:53 PM
#7044   Pipeline : TNX-1800 (Coronavirus Vaccine) Tonix Pharmaceuticals Holding AllGold818 08/31/20 07:43:47 PM
#7043   $TNXP Tonix Pharmaceuticals Reports Second Quarter 2020 Financial mick 08/29/20 12:46:34 PM
#7042   $TNXP appreciate dd. wow read mick 08/29/20 12:33:32 PM
PostSubject
Consent Preferences